AKRO
Akero Therapeutics, Inc.
Biotechnology
Market Cap$4.50B
5Y Perf.+20.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
AKRO vs GPCR
Revenue, margins, valuation, and 5-year total return — side by side.
GPCR
Structure Therapeutics Inc.
Biotechnology
Market Cap$2.25B
5Y Perf.+40.1%
AKRO vs GPCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AKRO | GPCR |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $4.50B | $2.25B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-293M | $-170M |
| Total Debt | $36M | $6M |
| Cash & Equiv. | $340M | $800M |
AKRO vs GPCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AKRO
GPCR
| Stock | Feb 23 | Dec 25 | Return |
|---|---|---|---|
| Akero Therapeutics,… (AKRO) | 100 | 120.1 | +20.1% |
| Structure Therapeut… (GPCR) | 100 | 140.1 | +40.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AKRO vs GPCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: GPCR leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Akero Therapeutics, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
AKRO
Akero Therapeutics, Inc.
The Income Pick
AKRO is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.35
- 198.3% 10Y total return vs GPCR's 50.6%
- Lower volatility, beta 0.35, Low D/E 4.9%, current ratio 19.38x
Best for: income & stability and long-term compounding
GPCR
Structure Therapeutics Inc.
The Growth Play
GPCR carries the broadest edge in this set and is the clearest fit for growth exposure.
- EPS growth -2.6%
- -18.6% revenue growth vs AKRO's -24.6%
- +47.2% vs AKRO's +27.7%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | GPCR | -18.6% revenue growth vs AKRO's -24.6% |
| Quality / Margins | AKRO | 4.0% margin vs GPCR's 2.3% |
| Stability / Safety | AKRO | Beta 0.35 vs GPCR's 0.96 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | GPCR | +47.2% vs AKRO's +27.7% |
| Efficiency (ROA) | GPCR | -14.4% ROA vs AKRO's -29.1%, ROIC -30.3% vs -55.3% |
AKRO vs GPCR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLGPCRLAGGINGAKRO
AKROAkero Therapeutics, I…
2leads
GPCRStructure Therapeutic…
3leads
6 Total Categories
CATEGORYLEADERvs AKROMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AKRO1/1
Valuation MetricsMultiples, price ratios, and targets
GPCR2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
GPCR8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
GPCR3/5
Risk & VolatilityBeta, volatility, and downside exposure
AKRO2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AKRO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
AKRO and GPCR operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | AKROAkero Therapeutic… | GPCRStructure Therape… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$318M | -$209M |
| Net IncomeAfter-tax profit | -$293M | -$170M |
| Free Cash FlowCash after capex | -$250M | -$159M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +5.7% | -29.6% |
AKRO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
GPCR leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | AKROAkero Therapeutic… | GPCRStructure Therape… |
|---|---|---|
| Market CapShares × price | $4.5B | $2.3B |
| Enterprise ValueMkt cap + debt − cash | $4.2B | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | -14.57x | -16.31x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 4.89x | 1.53x |
| Price / FCFMarket cap ÷ FCF | — | — |
GPCR leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
GPCR leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
GPCR delivers a -15.1% return on equity — every $100 of shareholder capital generates $-15 in annual profit, vs $-31 for AKRO. GPCR carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to AKRO's 0.05x. On the Piotroski fundamental quality scale (0–9), GPCR scores 3/9 vs AKRO's 2/9, reflecting mixed financial health.
| Metric | AKROAkero Therapeutic… | GPCRStructure Therape… |
|---|---|---|
| ROE (TTM)Return on equity | -30.6% | -15.1% |
| ROA (TTM)Return on assets | -29.1% | -14.4% |
| ROICReturn on invested capital | -55.3% | -30.3% |
| ROCEReturn on capital employed | -42.4% | -24.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | 0.05x | 0.00x |
| Net DebtTotal debt minus cash | -$304M | -$793M |
| Cash & Equiv.Liquid assets | $340M | $800M |
| Total DebtShort + long-term debt | $36M | $6M |
| Interest CoverageEBIT ÷ Interest expense | -62.41x | — |
GPCR leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
GPCR leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AKRO five years ago would be worth $19,996 today (with dividends reinvested), compared to $15,058 for GPCR. Over the past 12 months, GPCR leads with a +47.2% total return vs AKRO's +27.7%. The 3-year compound annual growth rate (CAGR) favors GPCR at 17.7% vs AKRO's 6.3% — a key indicator of consistent wealth creation.
| Metric | AKROAkero Therapeutic… | GPCRStructure Therape… |
|---|---|---|
| YTD ReturnYear-to-date | — | -42.5% |
| 1-Year ReturnPast 12 months | +27.7% | +47.2% |
| 3-Year ReturnCumulative with dividends | +20.1% | +63.1% |
| 5-Year ReturnCumulative with dividends | +100.0% | +50.6% |
| 10-Year ReturnCumulative with dividends | +198.3% | +50.6% |
| CAGR (3Y)Annualised 3-year return | +6.3% | +17.7% |
GPCR leads this category, winning 3 of 5 comparable metrics.
Risk & Volatility
AKRO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AKRO is the less volatile stock with a 0.35 beta — it tends to amplify market swings less than GPCR's 0.96 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AKRO currently trades 95.3% from its 52-week high vs GPCR's 41.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AKROAkero Therapeutic… | GPCRStructure Therape… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.35x | 0.96x |
| 52-Week HighHighest price in past year | $57.35 | $94.90 |
| 52-Week LowLowest price in past year | $37.28 | $15.80 |
| % of 52W HighCurrent price vs 52-week peak | +95.3% | +41.3% |
| RSI (14)Momentum oscillator 0–100 | 70.4 | 30.2 |
| Avg Volume (50D)Average daily shares traded | 0 | 953K |
AKRO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates AKRO as "Buy" and GPCR as "Buy". Consensus price targets imply 193.1% upside for GPCR (target: $115) vs -11.4% for AKRO (target: $48).
| Metric | AKROAkero Therapeutic… | GPCRStructure Therape… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $48.40 | $114.75 |
| # AnalystsCovering analysts | 14 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
GPCR leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). AKRO leads in 2 (Income & Cash Flow, Risk & Volatility).
Best OverallStructure Therapeutics Inc. (GPCR)Leads 3 of 6 categories
Loading custom metrics...
AKRO vs GPCR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is AKRO or GPCR a better buy right now?
Analysts rate Akero Therapeutics, Inc.
(AKRO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AKRO or GPCR?
Over the past 5 years, Akero Therapeutics, Inc.
(AKRO) delivered a total return of +100. 0%, compared to +50. 6% for Structure Therapeutics Inc. (GPCR). Over 10 years, the gap is even starker: AKRO returned +198. 3% versus GPCR's +50. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AKRO or GPCR?
By beta (market sensitivity over 5 years), Akero Therapeutics, Inc.
(AKRO) is the lower-risk stock at 0. 35β versus Structure Therapeutics Inc. 's 0. 96β — meaning GPCR is approximately 175% more volatile than AKRO relative to the S&P 500. On balance sheet safety, Structure Therapeutics Inc. (GPCR) carries a lower debt/equity ratio of 0% versus 5% for Akero Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — AKRO or GPCR?
On earnings-per-share growth, the picture is similar: Structure Therapeutics Inc.
grew EPS -2. 6% year-over-year, compared to -29. 8% for Akero Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AKRO or GPCR?
Akero Therapeutics, Inc.
(AKRO) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Structure Therapeutics Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AKRO leads at 0. 0% versus 0. 0% for GPCR. At the gross margin level — before operating expenses — AKRO leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AKRO or GPCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AKRO or GPCR better for a retirement portfolio?
For long-horizon retirement investors, Akero Therapeutics, Inc.
(AKRO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35), +198. 3% 10Y return). Both have compounded well over 10 years (AKRO: +198. 3%, GPCR: +50. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AKRO and GPCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.